(19)

(11)

EP 4 823 631 A2

(12)

(88) Date of publication A3: 14.08.2025 (43) Date of publication: 21.10.2026 Bulletin 2026/43 (21) Application number: 24904819.0 (22) Date of filing: 11.12.2024

(51) International Patent Classification (IPC):  A61K 48/00(2006.01) C12N 15/87(2006.01) C12N 15/63(2006.01) C12N 15/11(2006.01) (52) Cooperative Patent Classification (CPC): C12N 15/907; C12N 15/113; C12N 9/226; C12N 2310/20 (86) International application number: PCT/US2024/059602 (87) International publication number: WO 2025/128722 (19.06.2025 Gazette 2025/25)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA Designated Validation States: GE KH MA MD TN (30) Priority: 11.12.2023 US 202363608616 P 05.01.2024 US 202463618090 P 26.01.2024 US 202463625640 P 29.01.2024 US 202463626486 P 03.05.2024 US 202463642047 P 25.09.2024 US 202463698812 P 09.10.2024 US 202463705442 P (71) Applicant: CREATE Medicines, Inc. Cambridge, MA 02139 (US)

(72) Inventors: GETTS, Daniel Cambridge, Massachusetts 02139 (US) WANG, Yuxiao Cambridge, Massachusetts 02139 (US) LIN, Ruei-Zeng Cambridge, Massachusetts 02139 (US) (74) Representative: Brand Murray Fuller LLP  First Floor, 111 Wardour Street London W1F 0UH London W1F 0UH (GB)